SUTRO BIOPHARMA, INC. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
SUTRO BIOPHARMA, INC. (STRO) had Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment of $27.35 million as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment · last filed 2026-03-23
- 2025-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $27.35M.
- 2024-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $48.63M.
- 2023-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $42.16M.
- 2022-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $37.91M.
| Period end | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment |
|---|---|
| 2025-12-31 | $27.35M 10-K · filed 2026-03-23 |
| 2024-12-31 | $48.63M 10-K · filed 2026-03-23 |
| 2023-12-31 | $42.16M 10-K · filed 2025-03-13 |
| 2022-12-31 | $37.91M 10-K · filed 2024-03-25 |
| 2021-12-31 | $33.43M 10-K · filed 2023-03-30 |
| 2020-12-31 | $36.83M 10-K · filed 2022-02-28 |
| 2019-12-31 | $33.85M 10-K · filed 2021-03-18 |
| 2018-12-31 | $29.30M 10-K · filed 2020-03-16 |
| 2017-12-31 | $25.01M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |